Welcome to our dedicated page for Interpace Biosciences SEC filings (Ticker: IDXG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Interpace Biosciences, Inc. filings document material-event disclosures for a thyroid-focused molecular diagnostics company. Recent 8-K reports furnish operating results and financial-condition updates tied to Interpace Diagnostics and its commercial thyroid testing franchise, including disclosures related to ThyGeNEXT and ThyraMIRv2.
The company’s regulatory filings also record capital-structure developments, including repayment of its term loan facility with BroadOak Capital Partners and conversion of Series C Preferred Stock into common stock. These disclosures provide formal records of results releases, Regulation FD communications, debt obligations, equity structure and business updates following the company’s transition away from PancraGEN.
Interpace Biosciences reported profitable first-quarter 2026 results while continuing its thyroid-only focus. Revenue was $9.0 million, down from $11.5 million a year earlier but up from $7.9 million on a Pro Forma basis that excludes the discontinued PancraGEN business. Gross margin improved to 65%, compared with 59% on a Pro Forma basis, reflecting better pricing and cost control in thyroid testing.
Income from continuing operations was $0.8 million versus $1.8 million a year ago, but higher than $0.4 million on a Pro Forma basis. Adjusted EBITDA reached $1.6 million, or 17% of revenue, up from $0.8 million and 10% on a Pro Forma basis. The company reaffirmed 2026 guidance for approximately 16% year-over-year thyroid revenue growth and highlighted higher average revenue per test, more accounts, and faster turnaround times. Interpace ended the quarter with $2.6 million in cash and no debt.
Interpace Biosciences reported lower revenue but remained profitable in the first quarter of 2026. Net revenue fell to $9.0 million from $11.5 million a year earlier, mainly because Medicare stopped reimbursing the discontinued PancraGEN test. Gross margin held at about 65%.
Net income decreased to $0.7 million from $1.6 million, while Adjusted EBITDA was $1.6 million versus $2.1 million. As of March 31, 2026, the company had $2.6 million in cash and $10.0 million in current assets against $4.0 million in current liabilities, and management believes available cash and forecast receipts will fund operations for at least 12 months.
In January 2026, all 47,000 shares of Series C Preferred Stock converted into about 23.3 million common shares, leaving 27,700,904 common shares outstanding. Two private equity investors now hold roughly 84% of the common stock. Interpace remains focused on its thyroid cancer tests ThyGeNEXT and ThyraMIR v2 and continues to evaluate financing and strategic alternatives, including a possible Nasdaq uplisting.
Interpace Biosciences, Inc. filed Amendment No. 1 to its Annual Report for the year ended December 31, 2025 to add Part III information on directors, executive compensation, security ownership, related-party matters and auditor fees that was originally expected to come from a proxy statement.
The filing details a five-member classified board, committee structures and independence determinations, and compensation for named executives. In 2025, CEO Thomas W. Burnell earned total compensation of $708,192, while CFO and COO Christopher McCarthy earned $468,265. Non-employee directors each received cash fees of up to $50,000.
The amendment also shows ownership concentration, with Ampersand 2018 Limited Partnership holding 13,861,386 shares (50.0%) and 1315 Capital II, L.P. holding 9,405,941 shares (34.0%) as of April 15, 2026, when 27,700,904 common shares were outstanding. Audit fees paid to EisnerAmper LLP were $320,250 for 2025. No new financial statements are included.
Interpace Biosciences reported Q4 2025 revenue of $9.2 million and full-year 2025 revenue of $38.7 million, both down versus 2024 but up versus thyroid-only pro forma comparisons. Income from continuing operations jumped to $22.8 million in Q4 and $25.0 million for the year, mainly from a one-time, non-cash tax-related accounting adjustment that released a deferred tax valuation allowance.
Thyroid testing remained the growth engine, with 2025 thyroid revenue up 21% and volume up 13% year-over-year. The company completed its shift to a thyroid-only diagnostics model, paid off its debt in Q4 2025, improved cash to $2.5 million, and moved stockholders’ equity from a deficit to a positive $22.4 million at year-end.
1315 Capital II, L.P. reported acquisition or exercise transactions in a Form 4 filing for IDXG. The filing lists transactions totaling 9,424,941 shares at a weighted average price of $2.02 per share. Following the reported transactions, holdings were 9,405,941 shares.
Ampersand 2018 Limited Partnership, a 10% owner of Interpace Biosciences, Inc., reported converting preferred stock into common shares. On January 20, 2026, it converted 28,000 Series C Convertible Preferred shares into 13,861,386 shares of common stock.
The preferred shares had a stated value of $1,000 per share and a conversion price of $2.02 per common share, which determines how many common shares are issued on conversion. Following this transaction, the reporting holder owned 13,861,386 common shares directly and no remaining Series C preferred shares.
Interpace Biosciences, Inc. filed a current report describing preliminary, unaudited revenue for the year ended December 31, 2025, as outlined in a related press release.
The company also reported that all outstanding shares of its Series C Preferred Stock were converted into shares of its common stock, simplifying its equity structure. The press release dated January 20, 2026 is furnished as an exhibit to the report and is not treated as filed for purposes of liability under the Exchange Act.
Interpace Biosciences, Inc. reported that on December 3, 2025 it fully repaid its outstanding term loan facility with BroadOak Capital Partners before the loan’s scheduled maturity. This means the company has cleared that specific debt obligation earlier than required, which can simplify its capital structure and reduce future interest payments. The update was shared through a press release attached as an exhibit, providing more detail on the repayment and its context for the business.
Interpace Biosciences, Inc. (IDXG) furnished an 8-K under Item 2.02 announcing results of operations and financial condition for the quarter ended September 30, 2025. The company issued a press release, included as Exhibit 99.1, providing the full details.
The information in Item 2.02, including Exhibit 99.1, is being furnished and is not deemed “filed” for purposes of Section 18 of the Exchange Act. The filing also lists the Cover Page Interactive Data File as Exhibit 104.